1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Dexcom Now Offers Providers G6 Pro Continuous Glucose Monitoring Systems

 
• By Marion Webb

Dexcom announced that providers can pre-order its G6 Pro continuous glucose monitoring system starting today with shipping starting 6 July. 

G6 Pro Image with Physician Reader

San Diego, CA-based diabetes company Dexcom Inc. announced that health care providers can begin pre-ordering the company’s G6 Pro continuous glucose monitoring (CGM) system on 8 June.

Dexcom’s G6 Pro, which earned US Food and Drug Administration clearance last October for people 2 years of age or older, is the first and only single-use professional CGM that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.